MTOR and lung carcinoma: In recent years, previous studies have affirmed that Rapa reversed cisplatin resistance in lung cancer to affect its progression, which is associated with the mTOR-mediated signaling pathway (Wangpaichitr et al., 2008; Wu et al., 2005).